Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq:…
Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE…
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
March 24, 2025 16:20 ET | Source: Bolt Biotherapeutics, Inc. BDC-4182 on…
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
March 24, 2025 16:05 ET | Source: Artiva Biotherapeutics, Inc. Initial data…
Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
March 19, 2025 04:00 ET | Source: Oxford BioTherapeutics Collaboration leverages OBT’s…
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15%…
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference
WESTLAKE VILLAGE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq:…
Revolo to Present at the 2025 AAAAI / WAO Joint Congress
February 10, 2025 12:00 ET | Source: Revolo Biotherapeutics GAITHERSBURG, Md. and…
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.…
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.…